Welcome to our dedicated page for Utime SEC filings (Ticker: WTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to follow UTime Ltd’s moves across smartphones, medical wearables, and a new tourism platform can feel like piecing together three different stories. Each quarter, the company files detailed reports that split revenue among these segments, outline costly R&D for health sensors, and disclose OEM production volumes—information investors can’t afford to miss but often struggle to locate.
Our platform fixes that problem. Stock Titan’s AI reads every UTime Ltd quarterly earnings report 10-Q filing the moment it hits EDGAR, then surfaces segment sales, cash-flow swings, and inventory changes in plain English. It turns a 200-page 10-K into a one-page digest—literally UTime Ltd annual report 10-K simplified. Need to track management’s trades? We stream UTime Ltd Form 4 insider transactions real-time so you spot buying or selling patterns before market open. You’ll also find a dedicated section for UTime Ltd 8-K material events explained, covering new supply contracts or healthcare partnerships within minutes of release.
Common questions such as “understanding UTime Ltd SEC documents with AI” are answered inline. Click once to see UTime Ltd insider trading Form 4 transactions, compare margins with our UTime Ltd earnings report filing analysis, or review the UTime Ltd proxy statement executive compensation tables without scrolling through footnotes. Whether you’re monitoring UTime Ltd executive stock transactions Form 4 or just want UTime Ltd SEC filings explained simply, Stock Titan delivers every form—10-K, 10-Q, 8-K, S-1, SC 13D—enhanced by real-time alerts and expert commentary, so you can act on facts instead of searching for them.
UTime Limited reported that its Chief Operating Officer, Yihuang Chen, resigned effective immediately on December 12, 2025. The company stated that Mr. Chen’s resignation was not due to any disagreement regarding its operations, policies, or practices, suggesting the departure is not tied to a disclosed internal dispute.
The company also indicated that it has not yet decided whether to hire a replacement Chief Operating Officer, leaving its future leadership structure for this role undecided. The report was signed by Chief Executive Officer Hengcong Qiu, emphasizing that the change is an official, board-level leadership transition.
UTime Limited reported that shareholders approved a Share Consolidation at an extraordinary general meeting on November 10, 2025. Voting results were 81,671,284 for, 1,994,216 against, and 25,928 abstentions. Holders of 83,691,428 Class A ordinary shares voted out of 194,410,153 issued and outstanding entitled to vote.
No fractional shares will be issued; any fractional entitlement will receive one full post‑consolidation share. The company anticipates its Class A ordinary shares will begin trading on a Share Consolidation basis on November 21, 2025. An amendment to the memorandum and articles will be filed with the Cayman Islands General Registry on or about November 11, 2025, and a related press release is provided as an exhibit.
UTime Limited filed a Form 6-K noting it issued a press release on November 5, 2025. The company said it is actively promoting its smart wearable devices to more international markets through its existing global distribution channels and partner network.
The filing includes the press release as Exhibit 99.1 and reflects a focus on expanding the reach of UTime’s wearables by leveraging current partners rather than new distribution structures.
UTime Limited (WTO) furnished a Form 6-K noting it issued a press release on its ongoing exploration in health data analysis, particularly the potential application of artificial intelligence technologies. The filing identifies the press release as Exhibit 99.1. This is an informational update about the company’s R&D focus area and does not describe a transaction or financing. The report is signed by Chief Executive Officer Hengcong Qiu.
UTime Limited furnished a Form 6‑K noting it issued a press release announcing the release of its smart ring product. The company states the press release is attached as Exhibit 99.1.
The announcement is dated October 30, 2025. This filing serves to formally report the product release to U.S. markets and provide the associated press release for reference.
UTime Limited reported the launch of a smartwatch with integrated blood pressure monitoring, expanding its product portfolio in the health technology sector. The update was disclosed via a Form 6-K and accompanied by a press release dated October 28, 2025.
This addition signals a push into health-focused wearables, aligning the company with growing demand for biometric tracking devices. The filing did not include financial details or performance metrics for the new product.
UTime Limited filed an amended Form 6-K to correct the record date tied to its upcoming Extraordinary General Meeting of Shareholders. The amendment updates Exhibit 99.1.
The Extraordinary General Meeting for holders of the Company’s Class A and Class B ordinary shares is planned for November 10, 2025 at 10:00 AM EST. UTime also furnished the meeting Notice and a Form of Proxy Card as Exhibits 99.1 and 99.2.
UTime Limited plans to hold an Extraordinary General Meeting of shareholders on November 10, 2025 at 10:00 AM EST. The meeting is for holders of the Company’s Class A and Class B ordinary shares. The company furnished the Notice of Extraordinary General Meeting as Exhibit 99.1 and the Form of Proxy Card as Exhibit 99.2 under this Form 6-K.
UTime Limited announced it entered into a Memorandum of Understanding with Hainan Fuxinyi Investment Co., Ltd. to collaborate over the next three years to co-develop a professional digital platform for elderly care services.
A press release with additional details is furnished as Exhibit 99.1 to this report.
UTime Limited priced and closed a best‑efforts public unit offering for approximate gross proceeds of $25 million, before fees and expenses. The Company sold 22,727,275 units at $1.10 per unit, each unit consisting of one Class A ordinary share and a warrant to purchase one Class A ordinary share.
Each warrant is exercisable immediately at $1.10 per share and expires one year from issuance, with customary anti‑dilution adjustments. The warrants include a cashless exercise alternative and a zero exercise price option under which holders may receive up to 14 shares per warrant, capped at an aggregate 318,181,850 shares. The offering was made under UTime’s effective Form F‑3 shelf via an October 16, 2025 prospectus supplement and closed on October 17, 2025.
Univest Securities acted as placement agent and will receive an 8.0% cash fee, a 1.0% non‑accountable expense allowance, and up to $150,000 in reimbursed expenses. Directors, officers and certain 5% holders agreed to 90‑day lock‑ups; the Company also agreed to a 90‑day issuance/registration standstill and a 120‑day prohibition on Variable Rate Transactions. Net proceeds will be used for general working capital and corporate purposes.
FAQ
What is the current stock price of Utime (WTO)?
What is the market cap of Utime (WTO)?
